Evidence map›Paper›PMID 37349949›Full record

Observational studyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023

Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis.

Beatriz Martín-Carro, Juan F Navarro-González, Alberto Ortiz, Carmine Zoccali, Jürgen Floege, Manuel A Ferreira, José L Gorriz-Teruel, Natalia Carrillo-López, Sara Panizo, Francesco Locatelli and 6 more

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 5 countries.

Beatriz Martín-CarroInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.ORCID 0000-0002-1683-6617
Juan F Navarro-GonzálezUnidad de Investigación y Servicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.ORCID 0000-0002-5015-7474
Alberto OrtizDepartment of Nephrology and Hypertension, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.ORCID 0000-0002-9805-9523
Carmine ZoccaliRenal Research Institute, New York, USA.ORCID 0000-0002-6616-1996
Jürgen FloegeRWTH Aachen University, Div. Nephrology, Aachen, Germany.
Manuel A FerreiraNova Medical School-Vice Dean, Lisboa, Portugal.
José L Gorriz-TeruelDepartment of Nephrology, Hospital Clínico Universitario, Valencia, Spain.ORCID 0000-0002-1134-9051
Natalia Carrillo-LópezInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
Sara PanizoInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
Francesco LocatelliDepartment of Nephrology, Alessandro Manzoni Hospital (past director), Lecco, Italy.ORCID 0000-0002-7505-261X
Markus KettelerDepartment of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany.
Gerard M LondonDepartment of Nephrology, Centre Hospitalier FH, Manhes, France.
Manuel Naves-DíazInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
Cristina Alonso-MontesInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
Jorge B Cannata-AndíaInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
José L Fernández-MartínInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias · ESAlessandro Manzoni Hospital · ITBiogem · ITHospital Curry Cabral · PTHospital Universitario Fundación Jiménez Díaz · ESRobert Bosch Hospital · DERWTH Aachen University · DEUniversidad de La Laguna · ESUniversidad de Oviedo · ESUniversitat de València · ES

Funding

European Union GRUPIN14-028Gobierno del Principado de AsturiasInstituto de Salud Carlos III RD06/0016/1013
6 · The paper itself

Abstract

backgroundDiabetic patients on haemodialysis have a higher risk of mortality than non-diabetic patients. The aim of this COSMOS (Current management of secondary hyperparathyroidism: a multicentre observational study) analysis was to assess whether bone and mineral laboratory values [calcium, phosphorus and parathyroid hormone (PTH)] contribute to this risk.

methodsCOSMOS is a multicentre, open-cohort, 3-year prospective study, which includes 6797 patients from 227 randomly selected dialysis centres in 20 European countries. The association between mortality and calcium, phosphate or PTH was assessed using Cox proportional hazard regression models using both penalized splines smoothing and categorization according to KDIGO guidelines. The effect modification of the association between the relative risk of mortality and serum calcium, phosphate or PTH by diabetes was assessed.

resultsThere was a statistically significant effect modification of the association between the relative risk of mortality and serum PTH by diabetes (P = .011). The slope of the curve of the association between increasing values of PTH and relative risk of mortality was steeper for diabetic compared with non-diabetic patients, mainly for high levels of PTH. In addition, high serum PTH (>9 times the normal values) was significantly associated with a higher relative risk of mortality in diabetic patients but not in non-diabetic patients [1.53 (95% confidence interval 1.07-2.19) and 1.17 (95% confidence interval 0.91-1.52)]. No significant effect modification of the association between the relative risk of mortality and serum calcium or phosphate by diabetes was found (P = .2 and P = .059, respectively).

conclusionThe results show a different association of PTH with the relative risk of mortality in diabetic and non-diabetic patients. These findings could have relevant implications for the diagnosis and treatment of chronic kidney disease-mineral and bone disorders.

Indexed as

CalciumDiabetes MellitusCalcium, DietaryHumansMineralsParathyroid HormonePhosphatesProspective StudiesRenal DialysisCalciumCalcium, DietaryMineralsParathyroid HormonePhosphateschronic kidney disease–mineral and bone disorders (CKD-MBD)diabeteshaemodialysismortalityPTH

Identifiers

PMID37349949
PMCPMC10615625
OpenAlexW4381715461

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.